Hyperfine Inc (HYPR)vsMerck & Company Inc (MRK)
HYPR
Hyperfine Inc
$0.72
+4.98%
HEALTHCARE · Cap: $73.43M
MRK
Merck & Company Inc
$146.72
-0.14%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 407338% more annual revenue ($67.38B vs $16.54M). MRK leads profitability with a 3.6% profit margin vs -210.7%. MRK earns a higher WallStSmart Score of 44/100 (D).
HYPR
Avoid30
out of 100
Grade: F
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYPR.
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.72
$62.06 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 44.8% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -101.2% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 44.8% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
HYPR profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.50 — expect wider price swings.
HYPR is growing revenue faster at 44.8% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneering force in medical technology, renowned for developing the world’s first FDA-cleared portable MRI system, which significantly enhances diagnostic imaging accessibility at the point of care. By combining innovation with cost-efficiency, the company improves patient outcomes and facilitates rapid clinical decision-making. As healthcare continues to evolve, Hyperfine is strategically positioned to capture growth opportunities within the expanding imaging diagnostics market, presenting a compelling investment prospect for institutional investors focused on transformative healthcare solutions.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?